This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marsollier, L.
Right arrow Articles by Cole, S. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marsollier, L.
Right arrow Articles by Cole, S. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2003, p. 1228-1232, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1228-1232.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Isolation of Three Mycobacterium ulcerans Strains Resistant to Rifampin after Experimental Chemotherapy of Mice

Laurent Marsollier,1* Nadine Honoré,2 Pierre Legras,3 Anne Lise Manceau,1 Henri Kouakou,4 Bernard Carbonnelle,1 and Stewart T. Cole2

Laboratoire de Bactériologie-Virologie-Hygiène Hospitalière, CHU, 49033 Angers Cedex 01,1 Unité de Génétique Moléculaire Bactérienne, Institut Pasteur, 75724 Paris Cedex 15,2 Animalerie Hospitalo-Universitaire, Faculté de Médecine, 49000 Angers, France,3 Institut Raoul Follereau, Adzopé, Côte d'Ivoire4

Received 17 May 2002/ Returned for modification 26 July 2002/ Accepted 23 December 2002

By use of a murine model for Buruli ulcer, Mycobacterium ulcerans was found to be susceptible to rifampin, with the MIC being 0.5 to 1 µg/ml. Three mutants were isolated after rifampin monotherapy. Two were resistant to rifampin at 8 µg/ml, and one was resistant to rifampin at 32 µg/ml. The mutants harbored Ser416Phe mutations and His420Tyr mutations in the rpoB gene, and these mutations have also been found to be responsible for rifampin resistance in the leprosy and tubercle bacilli. The results indicate that while rifampin may be active against M. ulcerans, it should never be used as monotherapy in humans.

* Corresponding author. Mailing address: Laboratoire de Bactériologie-Virologie-Hygiène, CHU, 49033 Angers, France. Phone 33 (0)2 41 35 47 09. Fax: 33 (0)2 41 35 41 64. E-mail: laurentmarsollier{at}hotmail.com.

Antimicrobial Agents and Chemotherapy, April 2003, p. 1228-1232, Vol. 47, No. 4
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.4.1228-1232.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chauty, A., Ardant, M.-F., Adeye, A., Euverte, H., Guedenon, A., Johnson, C., Aubry, J., Nuermberger, E., Grosset, J. (2007). Promising Clinical Efficacy of Streptomycin-Rifampin Combination for Treatment of Buruli Ulcer (Mycobacterium ulcerans Disease). Antimicrob. Agents Chemother. 51: 4029-4035 [Abstract] [Full Text]  
  • Ji, B., Chauffour, A., Robert, J., Lefrancois, S., Jarlier, V. (2007). Orally Administered Combined Regimens for Treatment of Mycobacterium ulcerans Infection in Mice. Antimicrob. Agents Chemother. 51: 3737-3739 [Abstract] [Full Text]  
  • Rybniker, J., Kramme, S., Small, P. L. (2006). Host range of 14 mycobacteriophages in Mycobacterium ulcerans and seven other mycobacteria including Mycobacterium tuberculosis - application for identification and susceptibility testing. J Med Microbiol 55: 37-42 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»